DEVICE CATEGORY · NCD
Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis
FDA classification: Unknown. Device class 3.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QuantiFERON-TB Gold Plus TestP010033/S053 | Qiagen | PMA supplement | Oct 14, 2026 | FDA |
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | May 26, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jan 26, 2026 | FDA | |
| Qiagen | PMA supplement | Jan 23, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Dec 19, 2025 | FDA | |
QuantiFERON-TB Gold Plus TestP010033/S051 | Qiagen | PMA supplement | Nov 21, 2025 | FDA |
| DiaSorin, Inc. | PMA supplement | Oct 10, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 28, 2025 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 21, 2025 | FDA | |
| DiaSorin, Inc. | PMA approval | Nov 26, 2019 | FDA | |
| Qiagen | PMA approval | Nov 28, 2001 | FDA |
Source information
Follow the FDA links to view the original records.






